WINTON GROUP Ltd Decreases Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

WINTON GROUP Ltd lessened its position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 70.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,997 shares of the company’s stock after selling 31,204 shares during the period. WINTON GROUP Ltd’s holdings in Fulcrum Therapeutics were worth $61,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Bank of New York Mellon Corp lifted its stake in shares of Fulcrum Therapeutics by 2.3% during the 4th quarter. Bank of New York Mellon Corp now owns 141,873 shares of the company’s stock valued at $667,000 after buying an additional 3,126 shares in the last quarter. American Century Companies Inc. lifted its position in shares of Fulcrum Therapeutics by 5.9% during the fourth quarter. American Century Companies Inc. now owns 120,611 shares of the company’s stock worth $567,000 after acquiring an additional 6,770 shares in the last quarter. Intech Investment Management LLC boosted its holdings in shares of Fulcrum Therapeutics by 74.9% in the fourth quarter. Intech Investment Management LLC now owns 30,499 shares of the company’s stock worth $143,000 after acquiring an additional 13,057 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Fulcrum Therapeutics by 1.0% in the third quarter. Geode Capital Management LLC now owns 1,320,862 shares of the company’s stock worth $4,716,000 after acquiring an additional 13,485 shares during the period. Finally, Walleye Capital LLC purchased a new position in shares of Fulcrum Therapeutics in the third quarter valued at $59,000. Institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Stock Down 4.3 %

Fulcrum Therapeutics stock opened at $2.88 on Tuesday. The stock has a market cap of $155.46 million, a price-to-earnings ratio of -9.29 and a beta of 2.20. The business has a 50-day simple moving average of $3.50 and a 200 day simple moving average of $3.68. Fulcrum Therapeutics, Inc. has a 52 week low of $2.78 and a 52 week high of $10.13.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.03). On average, research analysts anticipate that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “neutral” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Fulcrum Therapeutics currently has an average rating of “Hold” and an average target price of $8.63.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.